INDIVIDUAL CORRECTION OF THE TREATMENT OF PATIENTS WITH HEPATOSPLENOMEGALY SYNDROME, TAKING INTO ACCOUNT THE PARAMETERS OF LIPID AND PROTEIN METABOLISM

  • E.M. Klimova
  • Yu.V. Kalashnikova
  • O.S. Merezhko
  • T.I. Kordon
Keywords: hepatosplenomegaly, liver cirrhosis, hepatosis, lipid metabolism, enzymes.

Abstract

Summary. Purpose: to identify the features of lipid metabolism in patients with hepatosplenomegaly syndrome (HSS) of various origins to develop an individualized approach to the treatment of patients with this pathology.

Materials and methods: blood serum of 73 patients with HSS on the background of liver cirrhosis complicated by portal hypertension, divided into 3 groups 1) with the etiological factor of hepatitis viruses HCV / HBV, 2) with autoimmune hepatitis with the etiological factor of the herpes group viruses CMV / VEB, 3) against the background of liver hepatosis and fermentopathies.

Results and its discussion. In patients with HSS, multidirectional changes in the synthesis of lipid fractions were observed, also associated with impaired protein metabolism, namely:

- with HSS against the background of viral hepatitis B and C, hypocholesterolemia and hypobetacholesterolemia were observed due to a decrease in cholesterol synthesis in hepatocytes; a decrease in the concentration of HDL is also associated with a violation of the process of cholesterol esterification due to a deficiency of the enzyme lecithin cholesterol acyltransferase, and an increase in the concentration of LDL is associated with a deficiency of the enzyme lipoprotein lipase in viral damage to hepatocytes.

- with HSS against the background of autoimmune hepatitis, no significant changes were observed in the synthesis of lipid fractions;

- in hepatosis (fermentopathies), type 5 hyperlipidemia with hypercholesterolemia and hypotriglyceridemia was found, which are a consequence of impaired formation and excretion of lipids from the liver, probably as a result of a decrease in the synthesis of apoproteins and indicate the accumulation of fat in hepatocytes and the formation of hepatosis.

Conclusion:

  1. Surgical or endovascular treatment of HSS against the background of liver cirrhosis or hepatosis needs to be supplemented with individualized metabolic drug therapy, including lipid-lowering therapy.
  2. When detecting hypocholesterolemia and hypobetacholesterolemia in the first group, lipid-lowering therapy is not indicated, whereas if type 5 hyperlipidemia with hypercholesterolemia and hypotriglyceridemia is detected in the group of patients with fatty hepatosis, lipid-lowering therapy is necessary.

References

1. Klіmova OM., Kordon TІ, Smachilo RM, Beloz'orov ІV, Bichenko KO, Merezhko OS, ta іn. Diferencіal'na dіagnostika і korekcіya metabolіchnih ta іmunologichnih porushen' u hvorih z cirozom pechіnki, uskladnenim gepatosplenomegalієyu ta portal'noyu gіpertenzієyu. Vіsnik HNMU «Aktual'nі problemi suchasnoї medicini». 2019;(4):31-41 [In Ukr.].
2. Grove J., Nielsen S., Zhong J., Bassendine M.F., Drummer H.E., Balfe P. et al. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J. Virol. 2008;(82):12020–12029. [PMC free article] [PubMed] [Google Scholar]. https://pubmed.ncbi.nlm.nih.gov/18829747//. doi: 10.1128/JVI.01569-08. Epub 2008 Oct 1.
3. Prentoe J., Jensen T.B., Meuleman P., Serre S.B., Scheel T.K., Leroux-Roels G. et al. Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. J. Virol. 2011;(85):2224–2234. [PMC free article] [PubMed] [Google Scholar] https://pubmed.ncbi.nlm.nih.gov/21123377/. doi: 10.1128/JVI.01594-10. Epub 2010 Dec 1.
4. Daniel J.F., Mohamed L.H., Mathieu L., Baumert T.F., Schuster C. Hepatitis C Virus, Cholesterol and Lipoproteins — Impact for the Viral Life Cycle and Pathogenesis of Liver Disease. Viruses. 2013;(5):1292-1324. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712309/. PMC3712309. PMID: 23698400. doi: 10.3390/v5051292.
5. Klimova O., Grechikhin G., Drozdova L., Kordon T. Features of immunity in patients with hypersplenism caused by liver cirrhosis. Norwegian Journal of development of the International Sciences. 2018;(2(18)):3 – 7. https://issuu.com/njd-iscience/docs/njd_18_2 [In Ukr.].
6. Kamyshnikov V.S. Tekhnika laboratornyh rabot v medicinskoj praktike – 4-e izd., pererab. i dop. M.: MEDpress-inform, 2016. 344 s [In Rus.].
7. Tkachenko L.I., Maleev V.V., Sarieva D.M. Narushenie lipidnogo obmena u bol'nyh hronicheskim virusnym gepatitom S. Arhiv" vnutrennej mediciny. 2015;(6(26)):50 – 56. https://doi.org/10.20514/2226-6704-2015-0-6-50-56. [In Rus.].
8. Gejvandova N.I., YAgoda A.V., Gurnickaya M.V., Pervushin YU.V. Virus-associirovannye narusheniya lipidnogo obmena pri hronicheskom gepatite S. Klinicheskaya gepatologiya. 2007.(3(4)):25-28 [In Rus.].
9. Poynard T., Ratziu V., McHutchison J. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. J. Hepatol. 2003.(38(1)):75-85. https://pubmed.ncbi.nlm.nih.gov/12829989/. doi: 10.1053/jhep.2003.50267.
10. Serfaty L., Andreani T., Giral P. Carbonell N., Chazouillères O., Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C J. Hepatol. 2001;(34):428-434. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4807145/. doi: 10.1016/S0168-8278(00)00036-2. [PubMed] [Google Scholar].
11. Solomennik A.O., Ancyferova N.V., Bondar' A.E., Mogilenec E.I., YUrko E.V., Gavrilov A.V. Sostoyanie pokazatelej lipidnogo obmena u bol'nyh hronicheskim gepatitom S. Vіsnik VDNZU «Ukraїns'ka medichna stomatologіchna akademіya». 2012;(12(3(39)):94 – 97. http://repo.knmu.edu.ua/bitstream/123456789/2163/1/%D0%A3%D0%9C%D0%A1%D0%90_2012_2.pdf [In Ukr.]
12. Makarov V.K., CHajnikova E.A. Vozrastnye osobennosti lipidnogo spektra syvorotki krovi u bol'nyh ostrym virusnym gepatitom A. Epidemiologiya i infekcionnye bolezni. 2007:(1):34-37. https://epidemiology-journal.ru/ru/archive. [In Rus.].
13. Marzouk D., Sass J., Bakr I., El Hosseiny M., Abdel-Hamid M., Rekacewicz C. et al. Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. Gut. 2007;(56):1105–1110. [PMC free article] [PubMed] [Google Scholar]. https://pubmed.ncbi.nlm.nih.gov/16956918/. doi: 10.1136/gut.2006.091983. Epub 2006 Sep 6.
14. Klimova E.M., Sushkov S.V., Timchenko M.E., Riabtsev R.S., Kordon T.I., Bychenko E.A. et al. Immunoreactivity changes in patients with gastrointestinal pathology against the background of chronic Helicobacter pylori infection. Surgery (Azerbaijan). 2019;(4):29-37 [In Azer.].
15. Klimova E.M., Kalashnikova YU.V., Kordon T.I., Lavinskaya E.V., Agarkova A.N., Osmanov R.R. i dr. Prediktory gemorragicheskih i tromboticheskih oslozhnenij sindroma gepatosplenomegalii. Harkіvs'ka hіrurgіchna shkola. 2020;1(100):148 – 154. https://surgical-school.com.ua/index.php/journal/article/view/82. doi: https://doi.org/10.37699/2308-7005.1.2020.25 [[In Ukr.].
16. Fadeenko G.D., Kushnir I.E., Nikiforova YA.V. Diagnostika nealkogol'noj zhirovoj bolezni pecheni: vozmozhnosti i perspektivy. Suchasna gastroenterologіya. 2017;(6):79-91. http://nbuv.gov.ua/UJRN/SGastro_2017_6_13 [In Ukr.].
17. Ramcharran D, Wahed AS, Conjeevaram HS, Evans RW, Wang T, Belle SH, et al. Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology. 2010;(52):854–863. https://europepmc.org/article/med/20690192. doi: 10.1002/hep.23796. PMID: 20690192 PMCID: PMC2938827.
Published
2020-12-14
How to Cite
Klimova, E., Kalashnikova, Y., Merezhko, O., & Kordon, T. (2020). INDIVIDUAL CORRECTION OF THE TREATMENT OF PATIENTS WITH HEPATOSPLENOMEGALY SYNDROME, TAKING INTO ACCOUNT THE PARAMETERS OF LIPID AND PROTEIN METABOLISM. Kharkiv Surgical School, (5-6), 14-21. https://doi.org/10.37699/2308-7005.5-6.2020.03
Section
QUESTIONS OF SURGERY OF PANCREATOBILIARY SYSTEM